C-reactive Protein Measurement for the Differentiation Between Tuberculous and Malignant Pleural Effusion

Thesis submitted for partial fulfillment of the master degree in Chest Diseases

Presented by

Rehab Hamdy Ahmed

M.B.B.ch.

Supervised by

Prof. Samiha Sayed Ahmed Ashmawi


Professor of pulmonary medicine Faculty of Medicine Ain Shams University

Dr. Hala Mohamed Salem

Assistant Prof. of pulmonary medicine Faculty of Medicine Ain Shams University

Faculty of Medicine
Ain Shams University
2015





LIST OF Abbreviations

ADA Adenosine deaminase AFB Acid Fast bacilli AFP Alpha - Fetoprotein	
AFP Alpha - Fetoprotein	
AIDS Acquired immunodeficiency syndrome	
ANA Anti-nuclear antibody	
ARDS Adult respiratory distress syndrome	
AS Ankylosing spondylitis	
CAP Community acquired pneumonia	
CBC Complete Blood Count	
CD Cluster of differentiation	
CEA Carcino embryonic antigen	
CO2 Carbon dioxide	
COPD Chronic obstructive pulmonary disease	
CRP C-reactive protein	
CSF Cerebrospinal fluid	
CT Computed tomography	
Cx Complement	
CXR Chest X-ray	
CYFRA 21-1 Cytokeratin -19 fragments	
DNA Deoxyribo nucleic acid	
ESR Erythrocyte sedimentation rate	
Fn Fibronectin	
FVC Forced Vital Capacity	
GIST Gastro intestinal stromal tumor	
H Hydrogen	
HAP Hospital acquired pneumonia	
HCC Hepato cellular carcinoma	
HS Highly significant	
Ig Immunoglobulin	
ILx Interleukin	
INF-y Gamma interferon	
LDH Lactate dehydrogenase	
LDL Low density lipoprotein	
LE Lupus erythromatosus	

MAF Migration activating factor MPE Malignant pleural effusion MIF Migration inhibitory factor MRI Magnetic resonance imaging mRNA Messenger ribonucleic acid NK Natural killer cell NO. Number NS Non-significant PAF Platelet activating factor PC Phosphokinase PO2 Partial pressure of oxygen PGE Prostaglandin E PID Pelvic inflammatory disease PMNL Polymorph nuclear leucocytes PPD Purified protein derivative RA Rheumatoid arthritis RAM Rapid agglutination method SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery VHS Very highly significant		
MIF Migration inhibitory factor MRI Magnetic resonance imaging mRNA Messenger ribonucleic acid NK Natural killer cell NO. Number NS Non-significant PAF Platelet activating factor PC Phosphokinase PO2 Partial pressure of oxygen PGE Prostaglandin E PID Pelvic inflammatory disease PMNL Polymorph nuclear leucocytes PPD Purified protein derivative RA Rheumatoid arthritis RAM Rapid agglutination method SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	MAF	Migration activating factor
MRI Magnetic resonance imaging mRNA Messenger ribonucleic acid NK Natural killer cell NO. Number NS Non-significant PAF Platelet activating factor PC Phosphokinase PO2 Partial pressure of oxygen PGE Prostaglandin E PID Pelvic inflammatory disease PMNL Polymorph nuclear leucocytes PPD Purified protein derivative RA Rheumatoid arthritis RAM Rapid agglutination method SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	MPE	Malignant pleural effusion
mRNA Messenger ribonucleic acid NK Natural killer cell NO. Number NS Non-significant PAF Platelet activating factor PC Phosphokinase PO2 Partial pressure of oxygen PGE Prostaglandin E PID Pelvic inflammatory disease PMNL Polymorph nuclear leucocytes PPD Purified protein derivative RA Rheumatoid arthritis RAM Rapid agglutination method SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	MIF	Migration inhibitory factor
NK Natural killer cell NO. Number NS Non-significant PAF Platelet activating factor PC Phosphokinase PO2 Partial pressure of oxygen PGE Prostaglandin E PID Pelvic inflammatory disease PMNL Polymorph nuclear leucocytes PPD Purified protein derivative RA Rheumatoid arthritis RAM Rapid agglutination method SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	MRI	
NK Natural killer cell NO. Number NS Non-significant PAF Platelet activating factor PC Phosphokinase PO2 Partial pressure of oxygen PGE Prostaglandin E PID Pelvic inflammatory disease PMNL Polymorph nuclear leucocytes PPD Purified protein derivative RA Rheumatoid arthritis RAM Rapid agglutination method SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	mRNA	Messenger ribonucleic acid
NS Non-significant PAF Platelet activating factor PC Phosphokinase PO2 Partial pressure of oxygen PGE Prostaglandin E PID Pelvic inflammatory disease PMNL Polymorph nuclear leucocytes PPD Purified protein derivative RA Rheumatoid arthritis RAM Rapid agglutination method SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	NK	
PAF Platelet activating factor PC Phosphokinase PO2 Partial pressure of oxygen PGE Prostaglandin E PID Pelvic inflammatory disease PMNL Polymorph nuclear leucocytes PPD Purified protein derivative RA Rheumatoid arthritis RAM Rapid agglutination method SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	NO.	Number
PC Phosphokinase PO2 Partial pressure of oxygen PGE Prostaglandin E PID Pelvic inflammatory disease PMNL Polymorph nuclear leucocytes PPD Purified protein derivative RA Rheumatoid arthritis RAM Rapid agglutination method SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	NS	
PO2 Partial pressure of oxygen PGE Prostaglandin E PID Pelvic inflammatory disease PMNL Polymorph nuclear leucocytes PPD Purified protein derivative RA Rheumatoid arthritis RAM Rapid agglutination method SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	PAF	Platelet activating factor
PGE Prostaglandin E PID Pelvic inflammatory disease PMNL Polymorph nuclear leucocytes PPD Purified protein derivative RA Rheumatoid arthritis RAM Rapid agglutination method SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	PC	Phosphokinase
PID Pelvic inflammatory disease PMNL Polymorph nuclear leucocytes PPD Purified protein derivative RA Rheumatoid arthritis RAM Rapid agglutination method SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	PO2	Partial pressure of oxygen
PMNL Polymorph nuclear leucocytes PPD Purified protein derivative RA Rheumatoid arthritis RAM Rapid agglutination method SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	PGE	
PPD Purified protein derivative RA Rheumatoid arthritis RAM Rapid agglutination method SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	PID	
RAM Rapid agglutination method SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	PMNL	Polymorph nuclear leucocytes
RAM Rapid agglutination method SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	PPD	Purified protein derivative
SAA Serum amyloid A SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	RA	Rheumatoid arthritis
SD Standard deviation SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	RAM	Rapid agglutination method
SLE Systemic lupus erythromatosus TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	SAA	
TBP Tuberculous pleuritis TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	SD	
TGF-B Transforming growth factor B TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	SLE	Systemic lupus erythromatosus
TLC Total lung capacity TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery		
TNF Tumour necrosing factor U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	TGF-B	
U/S Ultrasound UTI Urinary tract infection VATS Video assisted thoracic surgery	TLC	Total lung capacity
UTI Urinary tract infection VATS Video assisted thoracic surgery	TNF	Tumour necrosing factor
VATS Video assisted thoracic surgery	U/S	Ultrasound
VHS Very highly significant	VATS	Video assisted thoracic surgery
	VHS	Very highly significant

LIST OF TABLES

Table	Title	Page
No.	Title	rage
1	Normal composition of pleural fluid	10
2	Forces governing pleural fluid production and removal	12
3	General causes of pleural effusions	17
4	Comparison between the two studied groups as	144
	regards demographic data	145
5	Comparison between the two studied groups as	146
	regards erythrocyte sedimentation rate findings	
7	Comparison between the two studied groups as	147
	regards pleural fluid chemistry	
8	CRP findings	149
9	Validity of C-reactive protein in diagnosis of both malignant and tuberculous effusion	149
10	Relation between C-reactive protein and smoking in both groups	150
11	The histopathological etiology of malignant pleural	151
	effusion among malignant paients	

LIST OF FIGURES

FigureNo.	Title	Page
1	Molecular structure and morphology of human	102
	CRP	
2	Binding sites of CRP	112
3	Nycocard	139
4	Comparison between the two studied groups	145
	as regards erythrocyte sedimentation rate	
	findings	
5	Comparison between the two studied groups	148
	as regards pleural fluid chemistry	
7	Relation between C-reactive protein and	150
	smoking in both groups	
8	The histopathological etiology of malignant	151
	peural effusion among malignant patients	

LIST OF CONTENTS

Contents	Page
Introduction	1
Aim of the Work	4
Review of Literature	5
Anatomy of the pleura	5
Pathogenesis of pleural effusions	14
Differential diagnosis of pleural effusions	19
Diagnosis of pleural effusion	64
C-reactive protein	100
Patients and Methods	
Results	143
Discussion	152
Summary	161
Conclusion	164
Recommendations	165
References	166
Arabic Summary	

Introduction

Introduction

Pleural effusion is defined as an accumulation of fluid in the pleural space in excess of 15-20 ml. The etiology for the development of a pleural effusion includes changes in the hydrostatic or colloid-osmotic pressure of pleural and pulmonary capillaries, changes in pleural vascular permeability and impaired lymphatic drainage (Ahmad et al., 2009).

The most frequent causes of pleural effusion are tuberculosis and neoplasm (Light, 1995). The diagnosis of effusion, need extensive procedure (Kinasewitz, 1997). These procedures include cytological, bacteriological, chemical analysis. Peek et al. (2000) advocated computerized axial tomography or chest U/S can reveal underlying lung disease or localized effusion.

Pleural needle biopsy, bronchoscopy, thoracoscopy or even open lung biopsy could evaluate undiagnosed pleural effusion after initial thoracocentesis (White et al., 2000). Infection caused by mycobacterium tuberculosis produces a range of immunological reactions so it would be expected that tuberculous pleural fluid contain a variety of immunologically important cytokines because of

Introduction 2

accumulation of immunocompetent cells in the pleural cavity (Ferrer, 1997). Pleural effusion is a common complication of malignant diseases occurs in 50% to 70% of malignancies (Narseen et al., 2000).

Carcinoma of the lung is the most common malignancy to invade the pleura (30%) and produces malignant effusions (Hsu, 1987). Carcinoma of breast is second in incidence (25%) (Iqbbal et al., 2000).

Lymphoma account for approximately 20% of all malignant effusions (Sahn, 1998). A less common cause of malignant pleural effusion is the primary tumor of the pleura; malignant mesothelioma (Hubbard, 1997).

CRP is an acute phase protein predominantly produced and secreted by hepatocytes. Other cells including lymphocytes, kupffer's cells, monocytes and macrophage can also produce CRP (Castell et al., 1990).

The induction of CRP synthesis is triggered by a number of cytokines, chiefly IL - 6, which is released from a variety of cell types but mainly from macrophages and monocytes at inflammatory sites (Gabay and Kushner, 1999).

Introduction 3

CRP level have been shown to increase in a number of pulmonary disease, notably bacterial infection, inflammation, neoplasia, pulmonary thromboembolism, and some pleural effusion related to other conditions (Mith and Lipwarth, 1995).

Although several studies have investigated the levels of CRP in various diseases states, few have focused on its role in patient with pleural effusion. The study has demonstrated that pleural fluid CRP level in tuberculous pleuritis is statistically significantly higher than malignant pleural effusion (Yilmaz et al., 2000).

The mechanism underlying the higher CRP in tuberculous pleuritis patient is not clear. They may be two possibilities. First, a local production of CRP in the pleural cavity of TBP patients enhanced by inducer cytokines especially IL - 6. Alternatively, it may result from leakage of plasma CRP via inflamed pleura because a correlation between serum and pleural fluid CRP levels was demonstrated (Yew et al., 2002).

Aim of the work

The aim of this study is to determine the validity of pleural fluid C-reactive protein concentration for the differentiation between tuberculous pleuritis (TBP) and malignant pleural effusion (MPE) in patient presenting with lymphocytic exudative pleural effusion.

Anatomy of the pleura

The pleura is the serous membrane that covers the lung parenchyma, the mediastinum, the diaphragm, and the rib cage. This structure is divided into the visceral pleura and the parietal pleura. The visceral pleura cover the lung parenchyma, not only at its points of contact with the chest wall, diaphragm, and mediastinum but also in the interlobar fissures. The parietal pleura lines the inside of the thoracic cavities. In accordance with the intrathoracic surfaces that it lines, it is subdivided into the costal, mediastinal, and diaphragmatic parietal pleura. The visceral and the parietal pleura meet at the lung root. At the pulmonary hilus, the mediastinal pleura is swept laterally onto the root of the lung. Posterior to the lung root, the pleura is carried downward as a thin double fold called the pulmonary ligament (Light, 2007).

The function of the pleura, like that of pericardium and peritoneum, is to provide two frictionless surfaces between a mobile structure and the containing walls of its cavity; a thin film of tissue fluid lubricates the surfaces. The cuff of pleura projected around the lung root is too big for it, as a coat cuff is too big for the wrist. It hangs down below as an empty fold, the pulmonary ligament, and an ill-

chosen name for it has nothing to do with the lung and is not a ligament. It provides dead space into which the lung root descends with descent of the diaphragm. More important, allows for expansion of vessels in the lung root, especially the inferior pulmonary vein, which always has 'dead space' near them (e.g. to the right superior vena cava, and in the femoral canal alongside the femoral vein) (Wang, 1985).

A film of fluid (pleural fluid) is normally present between the parietal and the visceral pleura. This thin layer of fluid act as lubricant and allows the visceral pleura covering the lung to slide along the parietal pleura lining the thoracic cavity during respiratory movements. The space, or potential space, between the two layers of pleura is designated as the pleural space. It is a potential space rather than an actual one (Wang, 1998).

The pleura is lined by a single layer of mesothlial cells. These cells are 20-40 um wide from 0.1 to 0.4 um, and have microvilli on their surface. The microvilli are distributed over the entire pleura, but are most prominent on the caudal as compared to the cephalic portions, and on the visceral as compared to the parietal pleura (Wang, 1985).

The microvilli increase the surface area of the pleura and thus enhance membrane transport and other membrane-dependent metabolic functions (**Light**, 1983).

Imuunohistochemically, the mesothelial cells express both low- and high- molecular-weight cytokeratin. The normal mesothelial cells are negative for reaction to vitamin, epithelial membrane antigen, carcinoembryonic antigen and factor VIII-related antigen (Dervan et al., 1986) and (Bolten et al., 1986).

The mesothelial cells in both visceral and parietal pleurae vary in thickness from less than $1\mu m$ to more than $4\mu m$ and from 16.4 ± 6.8 to $41.9\pm9.5\mu m$ in diameter. Their shape may vary according to their location in the pleural membrane (Wang, 1985).

Blood Supply of the Pleura:

The parietal pleura receives its blood supply from the systemic capillaries. Small branches of the intercostal arteries supply the costal pleura, whereas the mediastinal pleura is supplied principally by the pericardiacophrenic artery. The diaphragmatic pleura is supplied by the superior phrenic and musculophrenic arteries. The venous drainage of the parietal pleura is primarily by the intercostal veins,